Tapewire

Nasdaq · USD

KZIA

KAZIA THERAPEUTICS LTD

Export transactions ↓
Tapewire entity
6537
SEC CIK
0001075880
Parsed reports
18

Last 12 months

Inside the activity.

0 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
June 19, 2026 Filed Jun 23, 2026 22:47 UTC
Levine James E.Chief Financial Officer
GrantEmployee Stock Option (right to buy) · Derivative 200,000 $0.00 Strike: $13.86 $0.00
Disclosure

SEC source: 0001213900-26-071231 · ownership.xml · derivative · entry 1

Levine James E. · CIK 0001463151 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: ADSs · 200,000 shares

Expires not disclosed

F1 · shares: Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

F1 · derivative.exercise_date: Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

F1 · derivative.expiration_date: Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

Read SEC document
June 19, 2026 Filed Jun 23, 2026 22:47 UTC
Rao SudhaChief Scientific Officer
GrantEmployee Stock Option (right to buy) · Derivative 250,000 $0.00 Strike: $18.48 $0.00
Disclosure

SEC source: 0001213900-26-071230 · ownership.xml · derivative · entry 1

Rao Sudha · CIK 0002132027 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: ADSs · 250,000 shares

Expires not disclosed

F1 · shares: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

F1 · derivative.exercise_date: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

F1 · derivative.expiration_date: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

Read SEC document
January 08, 2026 Filed Jul 8, 2026 20:59 UTC GrantEmployee Stock Option (right to buy) · Derivative 100,000 $0.00 Strike: $9.10 $0.00
Disclosure

SEC source: 0001213900-26-076431 · ownership.xml · derivative · entry 1

Coffey Steven R. S. · CIK 0002121676 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: ADSs · 100,000 shares

Expires not disclosed

F1 · shares: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.exercise_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.expiration_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

Read SEC document
January 08, 2026 Filed Jul 8, 2026 20:59 UTC
Friend John E. IIChief Executive Officer
GrantRestricted Share Units · Derivative 150,000 $0.00 $0.00
Disclosure

SEC source: 0001213900-26-076430 · ownership.xml · derivative · entry 2

Friend John E. II · CIK 0001704021 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: ADSs · 150,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer.

F2 · derivative.exercise_date: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer.

F2 · derivative.expiration_date: Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer.

Read SEC document
January 08, 2026 Filed Jul 8, 2026 20:59 UTC
Friend John E. IIChief Executive Officer
GrantEmployee Stock Option (right to buy) · Derivative 500,000 $0.00 Strike: $6.78 $0.00
Disclosure

SEC source: 0001213900-26-076430 · ownership.xml · derivative · entry 1

Friend John E. II · CIK 0001704021 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: ADSs · 500,000 shares

Expires not disclosed

F1 · shares: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.exercise_date: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.expiration_date: Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

Read SEC document
January 08, 2026 Filed Jul 8, 2026 20:58 UTC
Bonacorda JeffreyVP, Finance and Controller
GrantEmployee Stock Option (right to buy) · Derivative 150,000 $0.00 Strike: $6.78 $0.00
Disclosure

SEC source: 0001213900-26-076429 · ownership.xml · derivative · entry 1

Bonacorda Jeffrey · CIK 0002115111 · VP, Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: ADSs · 150,000 shares

Expires not disclosed

F1 · shares: Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.exercise_date: Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.expiration_date: Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

Read SEC document
January 08, 2026 Filed Jul 8, 2026 20:58 UTC GrantEmployee Stock Option (right to buy) · Derivative 100,000 $0.00 Strike: $9.10 $0.00
Disclosure

SEC source: 0001213900-26-076428 · ownership.xml · derivative · entry 1

Davidson Ebru · CIK 0002135805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: ADSs · 100,000 shares

Expires not disclosed

F1 · shares: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.exercise_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.expiration_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

Read SEC document
January 08, 2026 Filed Jul 8, 2026 20:57 UTC GrantEmployee Stock Option (right to buy) · Derivative 75,000 $0.00 Strike: $6.78 $0.00
Disclosure

SEC source: 0001213900-26-076426 · ownership.xml · derivative · entry 1

APPLE ROBERT F · CIK 0001054942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: ADSs · 75,000 shares

Expires not disclosed

F1 · shares: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.exercise_date: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.expiration_date: Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

Read SEC document
January 08, 2026 Filed Jul 8, 2026 20:57 UTC
Cain DavidDirector, CMC
GrantEmployee Stock Option (right to buy) · Derivative 100,000 $0.00 Strike: $9.10 $0.00
Disclosure

SEC source: 0001213900-26-076427 · ownership.xml · derivative · entry 1

Cain David · CIK 0002125950 · Director, CMC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: ADSs · 100,000 shares

Expires not disclosed

F1 · shares: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.exercise_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

F1 · derivative.expiration_date: Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.